MedTrace Logo

Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora

NCT01861964 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-11-28

No results posted yet for this study

Summary

Human and animal studies demonstrate that xylooligosaccharides (XOS) are a highly efficacious prebiotic ingredient that delivers benefits at a minimum level of 1.4 g/day (d), which is much lower than levels required by fructooligosaccharides (FOS, 5 g/d) or galactooligosaccharides (GOS, 8 g/d). XOS promotes gastrointestinal regularity and relieves diarrhea and constipation at 0.7 g/d and 1.4 g/d, respectively. Xylooligosaccharides may also reduce blood cholesterol and may improve glycemic control, although more data from clinical trials are needed to confirm preliminary findings.

Conditions

  • Bifidobacteria
  • Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Placebo (Maltodextrin)

Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)

DIETARY_SUPPLEMENT

Xylooligosarcharide 1.4g

8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal

DIETARY_SUPPLEMENT

Xylooligosarcharide 2.8g

8 capsules (520 mg/capsule) to be taken in the morning and in the evening

Sponsors & Collaborators

Principal Investigators

  • David Heber, MD, PhD · UCLA Center for Human Nutrition

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01861964 on ClinicalTrials.gov